SEC Form 4 · accession 0000947871-26-000625

Shattuck Labs, Inc. · STTK

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

ORBIMED ADVISORS LLC

Director

OrbiMed Genesis GP LLC

Director

OrbiMed Capital GP IX LLC

Director

Period of report

Jun 11, 2026

Accepted (ET)

Jun 15, 2026 · 6:12 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001680367

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F3,F5	holding	—	—		—	5,255,106	I	See Footnote
Common Stock^F4,F5	holding	—	—		—	1,051,021	I	See Footnote

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Pre-Funded Warrants (right to buy)^F1,F3,F5,F2	$0.0001	Jun 11, 2026	P	1,041,667	A	—	—	Common Stock	1,041,667	26,519,541	I
Pre-Funded Warrants (right to buy)^F1,F4,F5,F2	$0.0001	Jun 11, 2026	P	208,333	A	—	—	Common Stock	208,333	5,303,908	I

Explanation of responses

F1On June 9, 2026, the Issuer announced a public offering of an aggregate of 10,879,376 shares of common stock ("Shares") at a price of $4.00 per Share and, in lieu of Shares to certain investors, pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 7,870,624 Shares at a price of $3.9999 per Pre-Funded Warrant. The Pre-Funded Warrant have an exercise price of $0.0001 per share and are exercisable at any time after the date of issuance. The public offering closed on June 11, 2026.
F2The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full.
F3These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX.
F4These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
F5This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya ("Ashiya"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.